Human Gene Therapy

Aims & Scope

Human Gene Therapy (HGT) is the premier, multidisciplinary journal covering all aspects of gene therapy.

The Journal publishes important advances in DNA, RNA, cell and immune therapies, validating the latest advances in research and new technologies.

Established in 1990, HGT provides a prestigious forum for publishing scientific and clinical research, including ethical, legal, regulatory, social, and commercial issues, which enables the advancement and progress of therapeutic procedures leading to improved patient outcomes, and ultimately, to curing diseases.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	4
2024	3.90

Journal Rank

Year	Value
2024	3913

Journal Citation Indicator

Year	Value
2024	1286

SJR (SCImago Journal Rank)

Year	Value
2024	1.137

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	163

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Biochemistry, Genetics and Molecular Biology, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

  Citation: 822

  Authors: Sylvie, Virginie, Philippe, Christian, Olivier, Marie Françoise, Carole

• High Levels of Foreign Gene Expression in Hepatocytes after Tail Vein Injections of Naked Plasmid DNA

  Citation: 806

  Authors: Guofeng, Vladimir, Jon A.

• Treatment of Leber Congenital Amaurosis Due to<i>RPE65</i>Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial

  Citation: 738

  Authors: William W., Tomas S., Shalesh, Artur V., Sharon B., Lili, Thomas J., Sanford L., Terence R., Barry J., Samuel G.

• Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN

  Citation: 689

  Authors: Christian, Nathan, Elizabeth L., Cecilia, Tamara, Peter, Laura K., James M.

• Episomal Vectors Rapidly and Stably Produce High-Titer Recombinant Retrovirus

  Citation: 621

  Authors: Todd M., Garry P.

• Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors

  Citation: 567

  Authors: Dirk, Andrea, Karola, Jürgen A.

• A Phase III Clinical Evaluation of Herpes Simplex Virus Type 1 Thymidine Kinase and Ganciclovir Gene Therapy as an Adjuvant to Surgical Resection and Radiation in Adults with Previously Untreated Glioblastoma Multiforme

  Citation: 553

  Authors: N. G.

• Activation of the Complement System by Synthetic DNA Complexes: A Potential Barrier for Intravenous Gene Delivery

  Citation: 491

  Authors: Christian, Karl, Francis C., Ernst

• Quantitative Analysis of the Packaging Capacity of Recombinant Adeno-Associated Virus

  Citation: 471

  Authors: Jian-Yun, Pei-Dong, Raymond A.

• Nonviral Vectors in the New Millennium: Delivery Barriers in Gene Transfer

  Citation: 461

  Authors: Makiya, Leaf

---